enGene Therapeutics Inc. (ENGN) stock

ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW

Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30

$2.41+0.13 (+5.70%)

Close on Nov 13, 2026Market cap $161.51MP/E –Yield 0.00%

enGene Therapeutics statistics

71 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 8, 2027 (estimated, before the open)
Last ex-dividend date: No dividends
Fundamentals through: Jul 31, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $161.51M; $272.32M
Enterprise Value: -$79.66M; $146.23M
PB Ratio: 0.70; 2.00
P/TBV Ratio: 0.70; 2.22

Share statisticsIndustry

Shares Outstanding: 67M; 58M
Shares Change (YoY): 30.7%; 10.8%
Shares Change (QoQ): 0.04%; 0.50%
Float: 67M; 49M
Shares Held by Insiders: 0.62%; 11.7%
Shares Held by Institutions: 61.1%; 56.4%

Short sellingIndustry

Short Interest: 2M; –
Short Interest Change: 8.08%; -0.80%
Days to Cover: 1.92; 5.15

Stock price statisticsIndustry

52-Week High: $12.25; –
52-Week Low: $1.40; –
20-Day Moving Average: $1.70; –
50-Day Moving Average: $1.79; –
200-Day Moving Average: $3.95; –
Average True Range (14): $0.16; –
Price Change (1 Week): 37.7%; -1.15%
Price Change (1 Month): 40.9%; -4.87%
Price Change (3 Months): 41.8%; -21.0%
Price Change (6 Months): 40.1%; -20.6%
Price Change (YTD): -73.3%; -23.6%
Price Change (1 Year): -72.2%; -22.4%
Price Change (3 Years): -69.9%; -29.5%
Average Volume (10 Days): 3M; –
Average Volume (20 Days): 2M; –
Average Volume (90 Days): 957,053; –
Relative Volume: 4.00; 0.70
Relative Strength Index (14): 75.1; 43.4
Volatility (1 Year): 111.8%; 80.1%
Beta (5 Years): -0.44; 1.07

Returns on capitalIndustry

Return on Equity (ROE): -60.5%; -49.9%
Return on Assets (ROA): -48.8%; -40.6%
Return on Invested Capital (ROIC): -3862.3%; -32.9%
Return on Capital Employed (ROCE): -52.3%; -37.9%

Financial positionIndustry

Current Ratio: 10.21; 3.30
Quick Ratio: 9.79; 2.39
Debt / Equity: 0.11; 0.49
Interest Coverage: -44.51; -6.35

GrowthIndustry

EPS Growth (3Y CAGR): -62.7%; 1.30%

EfficiencyIndustry

Profits Per Employee: -$1.59M; -$689.41K
Employee Count: 82; 74
WACC: 7.88%; 10.2%

Income statement (TTM)Industry

Operating Income: -$136.65M; -$21.37M
Pretax Income: -$130.86M; -$12.95M
Net Income: -$130.36M; -$22.35M
EBITDA: -$135.96M; -$17.21M

Balance sheetIndustry

Cash & Short-Term Investments: $266.32M; $68.68M
Total Debt: $25.16M; $116.91M
Net Cash (Debt): $241.17M; $17.76M
Net Cash Per Share: $3.60; $0.80
Equity (Book Value): $230.29M; $53.89M
Book Value Per Share: $3.44; $1.50
Tangible Book Value: $230.29M; $27.13M
Working Capital: $250.69M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$103.31M; -$12.38M
Capital Expenditures: -$688.00K; -$1.00M
Free Cash Flow: -$104.00M; -$18.21M
FCF Per Share: -$1.55; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -80.7%; -21.8%
FCF Yield: -64.4%; -9.44%
Dividend Yield: 0.00%; 1.88%
Shareholder Yield: 0.00%; 0.00%
Dividend Per Share: $0.00; $0.83
Years of Dividend Growth: 0; 0

Taxes and interestIndustry

Interest Expense: $3.07M; $2.90M
Income Tax: -$497.00K; $73.00K

Scores and fair valueIndustry

Altman Z-Score: -1.11; 0.23
Piotroski F-Score: 1; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	ENGN	S&P 500	Difference	ENGN per year	S&P 500 per year
1 month	+47.9%	-3.0%	+50.9 pts
3 months	+42.6%	-2.8%	+45.4 pts
Year to date	-73.3%	+11.5%	−84.8 pts
1 year	-71.4%	+13.5%	−84.9 pts
3 years	-72.8%	+77.7%	−150.5 pts	-35.2%	+21.1%
5 years	-95.1%	+72.6%	−167.7 pts	-45.2%	+11.5%
10 years	-95.1%	+308.2%	−403.2 pts	-26.0%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

2M ENGN shares were sold short on Oct 30, 2026, up 8.1% from the previous report. At recent volumes it would take 1.9 days to buy them back. Over the last 20 sessions, 36.5% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	1,623,750	+8.1%	847,021	1.9
Oct 15, 2026	1,502,316	+7.7%	801,510	1.9
Sep 30, 2026	1,394,394	+16.2%	770,258	1.8
Sep 15, 2026	1,199,676	-2.1%	700,551	1.7
Aug 31, 2026	1,225,010	-18.1%	688,120	1.8
Aug 14, 2026	1,495,277	-13.7%	680,801	2.2
Jul 31, 2026	1,733,296	+5.7%	680,561	2.5
Jul 15, 2026	1,640,215	+43.7%	1,255,969	1.3
Jun 30, 2026	1,141,694	-17.9%	1,116,776	1.0
Jun 15, 2026	1,390,080	-14.3%	859,253	1.6
May 29, 2026	1,622,269	+11.5%	1,466,173	1.1
May 15, 2026	1,455,269	-27.4%	5,752,614	1.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?